Therapeutic Application of Empagliflozin, Sitagliptin, and Metformin for Advancing Overall Wellness in T2D: Evidence Review for Practitioners in 2025
Hyperglycemia in T2D plays a pivotal role in diabetic microvascular complications; however, reducing HbA1c offers only modest benefit in mitigating cardio-renal complications, which are the major causes of T2DM-related mortality…